Showing results (31-40 of 74) with videos related to
Sort By:
Pageof 8
Haematologica|March 15, 2006
Long-term follow-up of autologous stem cell transplantation after intensive chemotherapy in patients with myelodysplastic syndrome or secondary acute myeloid leukemiaSophie Ducastelle, Lionel Adès, Claude Gardin, et al.The Hematology Journal : the Official Journal of the European Haematology Association|March 30, 2004
Rescue therapy combining intermediate-dose cytarabine with amsacrine and etoposide in relapsed adult acute lymphoblastic leukemiaOumedaly Reman, Agnes Buzyn, Veronique Lhéritier, et al.Cell Cycle (Georgetown, Tex.)|June 10, 2011
Hypomethylating agents reactivate FOXO3A in acute myeloid leukemiaSylvain Thépot, Elodie Lainey, Thomas Cluzeau, et al.Haematologica|December 31, 2016
Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the <i>Groupe Francophone Des Myélodysplasies</i>Lionel Ades, Thomas Prebet, Aspasia Stamatoullas, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 14, 2010
Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association groupNicolas Boissel, Olivier Nibourel, Aline Renneville, et al.Haematologica|August 5, 2018
Gemtuzumab ozogamicin for <i>de novo</i> acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trialJuliette Lambert, Cécile Pautas, Christine Terré, et al.American Journal of Hematology|June 11, 2013
Outcome of older patients with acute myeloid leukemia in first relapseClémentine Sarkozy, Claude Gardin, Nathalie Gachard, et al.Blood|November 7, 2008
Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 studyLionel Adès, Simone Boehrer, Thomas Prebet, et al.Blood|March 8, 2007
Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trialClaude Gardin, Pascal Turlure, Thierry Fagot, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2012
Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and olderClaude Gardin, Sylvie Chevret, Cécile Pautas, et al.Pageof 8